RxDoctor Payments Data

James Murphey, MD

Internal Medicine · Cleveland, GANPI 1740472208

Payments from drug & device makers

$394in general payments, 2019–2025

Across 22 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$100
  • Abbott$79
  • Pfizer$51
  • Kvk-tech, Inc.$31
  • Dexcom, Inc.$27
  • Inspire Medical Systems, Inc.$24
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK6$100
Abbott4$79
Pfizer3$51
Kvk-tech, Inc.2$31
Dexcom, Inc.1$27
Inspire Medical Systems, Inc.1$24
Amgen1$20
Phadia US Inc.1$19
Novo Nordisk1$16
AstraZeneca1$15
Sanofi Pasteur Inc.1$12

How this compares

$394 in reported general payments places this provider in the 50th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$124,390
Medicare patients
313
Services billed
3,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$166,493
EliquisApixaban77$103,672
JardianceEmpagliflozin83$90,490
FarxigaDapagliflozin Propanediol47$72,457
TrulicityDulaglutide52$66,915
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$51,653
MounjaroTirzepatide30$41,715
Tresiba Flextouch U-200Insulin Degludec19$41,416
Tresiba Flextouch U-100Insulin Degludec41$31,804
ProliaDenosumab18$30,384
XareltoRivaroxaban18$29,799
Breo ElliptaFluticasone/Vilanterol57$28,568
JanuviaSitagliptin Phosphate33$24,405
RybelsusSemaglutide12$22,449
Victoza 3-PakLiraglutide16$20,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$16$188,942144 claims
PfizerEliquis$51$103,67277 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix, Arexvy$100$101,434176 claims
AstraZenecaFarxiga, Symbicort$15$79,75062 claims
AmgenProlia$20$30,38418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Cleveland

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →